Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Novo Nordisk A/S. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$713.99 -1.21 (-0.17%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$714.40 +0.41 (+0.06%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company has a strong market capitalization of approximately $686 billion, indicating robust investor confidence and stability.
  • Eli Lilly and Co recently reported a significant increase in quarterly revenue, showcasing a year-over-year growth of over 45%, which reflects strong demand for its products.
  • The current stock price is around $1,050, which is supported by a majority of analysts rating it as a "buy," suggesting positive future performance.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, reporting $3.34 per share against a consensus estimate of $4.64, which may raise concerns about future profitability.
  • Some analysts have downgraded their ratings, with HSBC reducing their target price significantly, indicating potential volatility in stock performance.
  • The P/E ratio of 61.85 suggests that the stock may be overvalued compared to its earnings, which could deter value investors looking for bargains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$676.67 billion
P/E Ratio
60.97
Consensus Rating
Moderate Buy
Consensus Price Target
$1,011.37 (+41.7% Upside)
Volume
2.63 million shares
Average Volume
3.62 million shares
Today's Range
$709.00
$719.64
50-Day Range
$713.99
$899.78
52-Week Range
$677.09
$972.53
Dividend Yield
0.79%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$153.12 +0.51 (+0.33%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$152.72 -0.40 (-0.26%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The company recently reported strong quarterly earnings, with earnings per share exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • Johnson & Johnson has a solid market capitalization of approximately $367.50 billion, reflecting its stability and significant presence in the healthcare sector.
  • The current stock price is around $152.50, which may present a buying opportunity for investors looking for value in a well-established company.

Cons of Johnson & Johnson

  • Despite its strong performance, the stock has shown volatility, with a beta of 0.42, indicating that it may not be as responsive to market movements, which could limit growth potential.
  • Analysts have mixed ratings on the stock, with some maintaining a "hold" rating, suggesting uncertainty about its future performance.
  • The company's payout ratio is 57.84%, which, while sustainable, indicates that a significant portion of earnings is distributed as dividends, potentially limiting reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$368.41 billion
P/E Ratio
23.02
Consensus Rating
Moderate Buy
Consensus Price Target
$170.88 (+11.6% Upside)
Volume
6.73 million shares
Average Volume
7.97 million shares
Today's Range
$152.21
$153.48
50-Day Range
$146.39
$165.89
52-Week Range
$140.68
$169.99
Dividend Yield
3.25%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$183.51 +0.97 (+0.53%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$183.14 -0.37 (-0.20%)
As of 05/23/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received multiple upgrades from analysts, including a recent upgrade to a "strong-buy" rating, indicating strong confidence in the company's future performance.
  • The stock price is currently around $180, which may present a buying opportunity for investors looking for potential growth.
  • AbbVie has a solid market capitalization of over $319 billion, suggesting a stable and established presence in the pharmaceutical industry.

Cons of AbbVie

  • The stock has experienced fluctuations, with a 12-month high of $218.66 and a low of $153.58, indicating volatility that may concern risk-averse investors.
  • AbbVie has a relatively high price-to-earnings (P/E) ratio, which may suggest that the stock is overvalued compared to its earnings potential.
  • Insider selling has been reported, with significant shares sold recently, which could signal a lack of confidence from those within the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$324.15 billion
P/E Ratio
76.46
Consensus Rating
Moderate Buy
Consensus Price Target
$210.95 (+15.0% Upside)
Volume
4.03 million shares
Average Volume
6.24 million shares
Today's Range
$181.72
$184.12
50-Day Range
$170.01
$212.21
52-Week Range
$153.58
$218.66
Dividend Yield
3.53%
Novo Nordisk A/S stock logo

4. Novo Nordisk A/S NYSE:NVO

$67.26 -0.91 (-1.33%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$67.30 +0.04 (+0.06%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $63.54, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Recent upgrades from analysts, including a "strong-buy" rating, indicate positive sentiment and potential for stock appreciation.
  • With a market capitalization of approximately $305.91 billion, Novo Nordisk is a well-established player in the pharmaceutical industry, suggesting stability and reliability.

Cons of Novo Nordisk A/S

  • Shares have recently fallen by 3.9%, which may indicate volatility and potential challenges in the market.
  • Some analysts have issued "underperform" and "sell" ratings, suggesting that there may be concerns about the company's future performance.
  • The stock has a relatively high price-to-earnings (P/E) ratio of around 20.72, which could imply that it is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$301.83 billion
P/E Ratio
20.44
Consensus Rating
Hold
Consensus Price Target
$135.00 (+100.7% Upside)
Volume
6.50 million shares
Average Volume
6.69 million shares
Today's Range
$66.60
$67.89
50-Day Range
$57.99
$78.91
52-Week Range
$57.00
$148.15
Dividend Yield
2.48%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$295.37 -1.30 (-0.44%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$294.68 -0.69 (-0.23%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $456.57, which reflects a strong market position and potential for growth.
  • UnitedHealth Group has demonstrated solid financial performance, with a recent quarterly revenue of over $109 billion, indicating robust demand for its services.
  • The company has a healthy return on equity of 26.69%, suggesting effective management and profitability relative to shareholder equity.

Cons of UnitedHealth Group

  • The company recently reported earnings per share that missed analysts' expectations, which could indicate challenges in meeting growth targets.
  • UnitedHealth Group's debt-to-equity ratio of 0.74 suggests a moderate level of debt, which could pose risks if market conditions change.
  • With a current ratio of 0.83, the company may face liquidity challenges, indicating it might struggle to cover short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$267.94 billion
P/E Ratio
19.06
Consensus Rating
Moderate Buy
Consensus Price Target
$441.87 (+49.6% Upside)
Volume
16.81 million shares
Average Volume
6.59 million shares
Today's Range
$291.64
$299.70
50-Day Range
$273.96
$599.10
52-Week Range
$248.88
$630.73
Dividend Yield
2.66%
Novartis stock logo

6. Novartis NYSE:NVS

$112.77 +0.27 (+0.24%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$114.26 +1.49 (+1.32%)
As of 05/23/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $109.57, which reflects a stable market position and potential for growth.
  • Analysts have recently upgraded Novartis AG to a "strong-buy" rating, indicating strong confidence in the company's future performance.
  • Institutional investors own a significant portion of the company, which often suggests stability and confidence in the company's management and strategy.

Cons of Novartis

  • Despite recent upgrades, there are still analysts who have rated the stock as "underweight," indicating some skepticism about its growth potential.
  • The stock has experienced fluctuations, with a twelve-month low of $96.06, which may raise concerns about its stability.
  • Recent reports indicate that some institutional investors, like Ameriprise Financial Inc., have reduced their holdings, which could signal a lack of confidence in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$238.21 billion
P/E Ratio
19.18
Consensus Rating
Hold
Consensus Price Target
$123.38 (+9.4% Upside)
Volume
898,860 shares
Average Volume
1.59 million shares
Today's Range
$111.96
$112.95
50-Day Range
$101.80
$114.35
52-Week Range
$96.06
$120.92
Dividend Yield
2.31%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$131.31 -0.19 (-0.14%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$131.94 +0.63 (+0.48%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $129.66, which may present a buying opportunity for investors looking to enter at a favorable price point.
  • Abbott Laboratories has a strong institutional ownership, with over 75% of its stock held by institutional investors, indicating confidence in the company's long-term performance.
  • The company has shown consistent growth in its various segments, including Established Pharmaceutical Products and Medical Devices, which are critical areas for future revenue generation.

Cons of Abbott Laboratories

  • Insider selling has been observed, with company insiders selling over 95,000 shares recently, which could indicate a lack of confidence in the stock's short-term performance.
  • Despite strong institutional backing, corporate insiders own only 0.46% of the company's stock, which may raise concerns about alignment between management and shareholder interests.
  • The healthcare sector can be highly volatile, and Abbott Laboratories may face challenges from regulatory changes or competitive pressures that could impact its profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$228.46 billion
P/E Ratio
17.16
Consensus Rating
Moderate Buy
Consensus Price Target
$142.59 (+8.6% Upside)
Volume
6.14 million shares
Average Volume
6.14 million shares
Today's Range
$130.43
$132.17
50-Day Range
$123.63
$135.52
52-Week Range
$99.71
$141.23
Dividend Yield
1.75%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$70.41 +0.46 (+0.66%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$70.40 -0.02 (-0.02%)
As of 05/23/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $69.66, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • AstraZeneca has received multiple upgrades from analysts, with a consensus rating of "Buy" and an average price target of $88.00, indicating strong potential for price appreciation.
  • The company reported a year-over-year revenue increase of 7.2%, showcasing its ability to grow and adapt in a competitive market.

Cons of AstraZeneca

  • The stock has experienced volatility, with a 52-week high of $87.68 and a low of $61.24, indicating potential risks associated with price fluctuations.
  • Despite recent revenue growth, the company reported a decline in EPS compared to the previous year, which may raise concerns about future profitability.
  • AstraZeneca's debt-to-equity ratio stands at 0.65, which, while manageable, suggests that the company is somewhat reliant on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.36 billion
P/E Ratio
31.16
Consensus Rating
Buy
Consensus Price Target
$88.00 (+25.0% Upside)
Volume
3.96 million shares
Average Volume
5.18 million shares
Today's Range
$69.91
$70.60
50-Day Range
$64.87
$76.52
52-Week Range
$61.24
$87.68
Dividend Yield
3.03%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$77.59 -0.25 (-0.32%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$77.70 +0.11 (+0.15%)
As of 05/23/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $77.81, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Merck has a strong market capitalization of approximately $195.38 billion, indicating a solid position in the industry and potential for stability.
  • The company has demonstrated resilience with a price-to-earnings ratio of 11.56, suggesting it may be undervalued compared to its earnings potential.

Cons of Merck & Co., Inc.

  • Merck's stock has a 52-week high of $134.63, which indicates that it has experienced significant price fluctuations, raising concerns about potential overvaluation.
  • The company has a debt-to-equity ratio of 0.79, which, while manageable, suggests that it carries a moderate level of debt that could impact financial flexibility.
  • Merck's 50-day moving average is $82.10, which is above the current stock price, indicating a potential downward trend that investors should monitor.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$194.83 billion
P/E Ratio
11.53
Consensus Rating
Moderate Buy
Consensus Price Target
$109.19 (+40.7% Upside)
Volume
10.90 million shares
Average Volume
12.55 million shares
Today's Range
$77.08
$77.90
50-Day Range
$73.46
$94.72
52-Week Range
$73.31
$134.63
Dividend Yield
4.16%
Intuitive Surgical stock logo

10. Intuitive Surgical NASDAQ:ISRG

$539.54 -3.13 (-0.58%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$541.62 +2.09 (+0.39%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $561, which reflects a strong market position and potential for growth.
  • Intuitive Surgical, Inc. reported earnings per share of $1.81, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a high net margin of 27.81%, suggesting effective cost management and profitability.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings (P/E) ratio of 87.93, which may suggest that the stock is overvalued compared to its earnings.
  • Insider selling has been significant, with a total of 32,700 shares sold recently, which could indicate a lack of confidence among executives.
  • The stock has experienced fluctuations, with a 12-month high of $616 and a low of $395.60, indicating volatility that may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$193.38 billion
P/E Ratio
84.17
Consensus Rating
Moderate Buy
Consensus Price Target
$596.05 (+10.5% Upside)
Volume
1.14 million shares
Average Volume
1.64 million shares
Today's Range
$529.15
$542.07
50-Day Range
$451.58
$565.94
52-Week Range
$396.15
$616.00
Dividend Yield
N/A
Boston Scientific stock logo

11. Boston Scientific NYSE:BSX

$104.49 -0.01 (-0.01%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$104.16 -0.32 (-0.31%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Recent analyst upgrades have significantly increased the target price for Boston Scientific Co., with several firms setting targets above $120, indicating strong market confidence.
  • The current stock price is around $106, reflecting a positive trend and potential for growth as analysts maintain a consensus "Buy" rating.
  • Boston Scientific Co. has a robust market capitalization of approximately $157 billion, suggesting a strong position in the medical technology sector.

Cons of Boston Scientific

  • The price-to-earnings ratio is relatively high at around 85, which may indicate that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • Insider sales have totaled over 265,000 shares recently, which could raise concerns about the executives' confidence in the company's future performance.
  • The company has a debt-to-equity ratio of 0.41, which, while manageable, suggests that it is not entirely debt-free, potentially impacting financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$154.59 billion
P/E Ratio
83.59
Consensus Rating
Buy
Consensus Price Target
$114.87 (+9.9% Upside)
Volume
5.21 million shares
Average Volume
6.39 million shares
Today's Range
$103.58
$104.87
50-Day Range
$89.78
$106.61
52-Week Range
$71.88
$107.17
Dividend Yield
N/A
Thermo Fisher Scientific stock logo

12. Thermo Fisher Scientific NYSE:TMO

$393.53 -6.95 (-1.74%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$399.95 +6.42 (+1.63%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is approximately $516.67, reflecting a strong market position and investor confidence in the company's growth potential.
  • Thermo Fisher Scientific Inc. recently reported earnings per share (EPS) of $5.15, exceeding analysts' expectations, which indicates robust financial performance and effective management.
  • The company has shown a year-over-year revenue increase, demonstrating its ability to grow even in competitive markets, which is a positive sign for long-term investors.

Cons of Thermo Fisher Scientific

  • Insider selling has been observed, with executives selling a total of 14,075 shares recently, which may raise concerns about the company's future prospects from those in the know.
  • The stock has experienced fluctuations, with a recent decrease in ownership percentages among insiders, which could signal a lack of confidence in the company's short-term performance.
  • Despite a positive earnings report, the overall market conditions can impact stock performance, and investors should be cautious of potential volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$148.56 billion
P/E Ratio
23.81
Consensus Rating
Moderate Buy
Consensus Price Target
$607.43 (+54.4% Upside)
Volume
2.32 million shares
Average Volume
1.87 million shares
Today's Range
$390.66
$396.34
50-Day Range
$393.53
$520.25
52-Week Range
$390.50
$627.88
Dividend Yield
0.42%
Amgen stock logo

13. Amgen NASDAQ:AMGN

$271.66 -0.24 (-0.09%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$272.85 +1.19 (+0.44%)
As of 05/23/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $304, reflecting a strong performance in the market.
  • Amgen Inc. reported a significant earnings per share (EPS) of $4.90 for the latest quarter, exceeding analyst expectations, which indicates robust financial health.
  • The company has shown a revenue increase of 9.4% compared to the same quarter last year, suggesting strong growth potential.

Cons of Amgen

  • The dividend payout ratio is 86.86%, which indicates that a large portion of earnings is being paid out as dividends, potentially limiting funds available for reinvestment in growth opportunities.
  • Insider transactions show a decrease in ownership by executives, which may raise concerns about their confidence in the company's future performance.
  • Corporate insiders own only 0.76% of the company's stock, suggesting limited alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.07 billion
P/E Ratio
35.98
Consensus Rating
Hold
Consensus Price Target
$309.22 (+13.8% Upside)
Volume
2.53 million shares
Average Volume
2.79 million shares
Today's Range
$269.13
$272.52
50-Day Range
$262.28
$316.04
52-Week Range
$253.30
$346.85
Dividend Yield
3.45%
Stryker stock logo

14. Stryker NYSE:SYK

$377.01 -1.27 (-0.33%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$378.25 +1.24 (+0.33%)
As of 05/23/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Recent analyst ratings indicate strong confidence in Stryker Co., with multiple firms assigning "buy" ratings and target prices above $400, suggesting potential for price appreciation.
  • The current stock price is around $394, which is near the average target price of $427.05, indicating that there may still be room for growth.
  • Stryker Co. has a solid market capitalization of approximately $150.63 billion, reflecting its strong position in the medical technology sector.

Cons of Stryker

  • The stock has a high PE ratio of 50.85, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent insider selling, including a significant transaction by a director, could indicate a lack of confidence in the stock's short-term performance.
  • Despite strong ratings, the stock has experienced volatility, with a fifty-two week low of $314.93, which may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$143.90 billion
P/E Ratio
48.58
Consensus Rating
Moderate Buy
Consensus Price Target
$427.30 (+13.3% Upside)
Volume
1.58 million shares
Average Volume
1.35 million shares
Today's Range
$371.27
$379.53
50-Day Range
$336.96
$394.63
52-Week Range
$314.93
$406.19
Dividend Yield
0.86%
Gilead Sciences stock logo

15. Gilead Sciences NASDAQ:GILD

$107.37 +0.63 (+0.59%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$106.38 -0.98 (-0.92%)
As of 05/23/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The company recently reported earnings per share of $1.81, surpassing analyst expectations, which indicates strong financial performance and potential for growth.
  • Gilead Sciences, Inc. has a solid return on equity of 31.63%, suggesting effective management and profitability relative to shareholder equity.
  • The current stock price is around $99, which is significantly lower than its fifty-two week high of $119.96, presenting a potential buying opportunity for investors looking for value.

Cons of Gilead Sciences

  • The company's revenue for the latest quarter was down 0.3% year-over-year, which may raise concerns about its growth trajectory.
  • Despite beating earnings expectations, the revenue fell short of analyst predictions, indicating potential challenges in meeting future growth targets.
  • Insider selling has occurred, with the CFO recently selling 2,500 shares, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.56 billion
P/E Ratio
290.19
Consensus Rating
Moderate Buy
Consensus Price Target
$110.55 (+3.0% Upside)
Volume
6.04 million shares
Average Volume
7.72 million shares
Today's Range
$105.58
$107.84
50-Day Range
$96.86
$112.39
52-Week Range
$62.07
$119.96
Dividend Yield
2.90%
Pfizer stock logo

16. Pfizer NYSE:PFE

$23.33 +0.29 (+1.28%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$23.33 0.00 (-0.02%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $23.51, which may present a buying opportunity for investors looking for value.
  • Pfizer Inc. recently reported earnings per share (EPS) of $0.92, exceeding analysts' expectations, indicating strong financial performance.
  • The company has a solid market capitalization of approximately $133.66 billion, reflecting its stability and presence in the biopharmaceutical industry.

Cons of Pfizer

  • Pfizer Inc. experienced a revenue decline of 7.8% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • The company's price-to-earnings (P/E) ratio is 16.67, which could indicate that the stock is overvalued compared to its earnings.
  • Analysts have adjusted price targets downward, with some setting targets as low as $24.00, reflecting cautious outlooks on the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$132.66 billion
P/E Ratio
16.55
Consensus Rating
Moderate Buy
Consensus Price Target
$29.17 (+25.0% Upside)
Volume
35.31 million shares
Average Volume
41.03 million shares
Today's Range
$22.88
$23.39
50-Day Range
$21.57
$26.20
52-Week Range
$20.92
$31.54
Dividend Yield
7.53%
Danaher stock logo

17. Danaher NYSE:DHR

$184.79 -2.69 (-1.44%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$184.64 -0.15 (-0.08%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. has received a consensus rating of "Moderate Buy" from analysts, indicating strong confidence in the company's future performance.
  • The current stock price is around $197.68, which is significantly lower than its one-year high of $281.70, suggesting potential for price appreciation.
  • Recent earnings reports show that Danaher Co. exceeded revenue expectations, reporting $5.74 billion, which reflects strong operational performance.

Cons of Danaher

  • Analysts have recently adjusted price targets downward, with some estimates dropping to $240.00, indicating potential concerns about future growth.
  • The stock has experienced volatility, with a beta of 0.80, suggesting it may not be as stable as some investors prefer.
  • Insider ownership is at 11.10%, which may raise concerns about alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$132.25 billion
P/E Ratio
35.00
Consensus Rating
Moderate Buy
Consensus Price Target
$263.24 (+42.5% Upside)
Volume
2.81 million shares
Average Volume
3.47 million shares
Today's Range
$183.05
$185.99
50-Day Range
$173.85
$212.97
52-Week Range
$171.00
$281.70
Dividend Yield
0.65%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$51.98 -0.53 (-1.01%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$51.79 -0.19 (-0.37%)
As of 05/23/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi's stock is currently trading around $52, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • The company recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and potential for growth.
  • Sanofi has increased its annual dividend to $2.0369 per share, reflecting a commitment to returning value to shareholders and a healthy dividend yield of approximately 3.1%.

Cons of Sanofi

  • Despite recent earnings growth, Sanofi's revenue has shown a year-over-year decline, which could raise concerns about the sustainability of its financial performance.
  • The stock is currently experiencing volatility, with trading volumes fluctuating significantly, which may indicate uncertainty among investors.
  • Sanofi's market cap is substantial, but the company faces intense competition in the pharmaceutical industry, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$131.32 billion
P/E Ratio
20.88
Consensus Rating
Buy
Consensus Price Target
$63.33 (+21.8% Upside)
Volume
1.83 million shares
Average Volume
2.37 million shares
Today's Range
$51.80
$52.37
50-Day Range
$49.21
$58.60
52-Week Range
$45.80
$60.12
Dividend Yield
3.16%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$436.00 +1.97 (+0.45%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$434.46 -1.54 (-0.35%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $475, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals Incorporated has a strong focus on developing therapies for cystic fibrosis, a market with significant unmet medical needs, potentially leading to high demand for their products.
  • Recent insider trading activity indicates confidence in the company's future, as executives have been actively managing their stock positions, which can be a positive signal for investors.

Cons of Vertex Pharmaceuticals

  • Insider sales have occurred recently, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The biotechnology sector is highly competitive, and Vertex Pharmaceuticals Incorporated faces challenges from other companies developing similar therapies, which could impact market share.
  • Recent decreases in insider ownership percentages may indicate potential volatility in stock performance, which could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$111.96 billion
P/E Ratio
-198.18
Consensus Rating
Moderate Buy
Consensus Price Target
$515.04 (+18.1% Upside)
Volume
1.43 million shares
Average Volume
1.42 million shares
Today's Range
$427.43
$436.59
50-Day Range
$421.16
$512.52
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

20. Medtronic NYSE:MDT

$80.70 -0.21 (-0.25%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$80.96 +0.26 (+0.32%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $86, which is near its fifty-two week high, indicating strong market performance and investor confidence.
  • Medtronic plc reported a quarterly earnings per share (EPS) of $1.39, exceeding analysts' expectations, which reflects the company's robust financial health and operational efficiency.
  • The company has a solid dividend yield of approximately 3.24%, providing a steady income stream for investors, which is particularly attractive in a low-interest-rate environment.

Cons of Medtronic

  • The company has a relatively high price-to-earnings (P/E) ratio of 26.27, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price growth.
  • Medtronic plc's revenue for the last quarter was slightly below analyst estimates, which could indicate challenges in meeting growth expectations.
  • The dividend payout ratio is quite high at 85.11%, which may raise concerns about the sustainability of future dividends if earnings do not grow as expected.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$103.51 billion
P/E Ratio
24.53
Consensus Rating
Hold
Consensus Price Target
$96.07 (+19.0% Upside)
Volume
10.57 million shares
Average Volume
6.82 million shares
Today's Range
$79.93
$80.82
50-Day Range
$80.70
$91.78
52-Week Range
$75.96
$96.25
Dividend Yield
3.24%
Bristol-Myers Squibb stock logo

21. Bristol-Myers Squibb NYSE:BMY

$46.88 -0.15 (-0.32%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$46.88 +0.00 (+0.01%)
As of 05/23/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • The current stock price is around $58, which is considered reasonable compared to its historical performance and potential for growth in the biopharmaceutical sector.
  • Bristol-Myers Squibb has a strong portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which could drive future revenue growth.
  • The company has received positive ratings from several analysts, with a consensus rating of "Hold" and a price target indicating potential upside, suggesting confidence in its stability.

Cons of Bristol-Myers Squibb

  • Analysts have expressed concerns, with some cutting their target prices, indicating potential volatility and uncertainty in the stock's future performance.
  • There are multiple "neutral" ratings from analysts, suggesting that while the company is stable, it may not present significant growth opportunities in the near term.
  • Recent price adjustments by major financial institutions reflect a cautious outlook on the company's ability to maintain its market position amidst increasing competition.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.40 billion
P/E Ratio
-10.61
Consensus Rating
Hold
Consensus Price Target
$58.00 (+23.7% Upside)
Volume
8.40 million shares
Average Volume
13.17 million shares
Today's Range
$46.49
$47.16
50-Day Range
$44.06
$61.09
52-Week Range
$39.35
$63.33
Dividend Yield
5.30%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$376.86 +0.22 (+0.06%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$376.63 -0.23 (-0.06%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. reported earnings per share (EPS) of $6.45 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • The company has a significant return on equity of over 586%, suggesting that it is highly effective at generating profits from its equity investments.
  • HCA Healthcare, Inc. has declared a quarterly dividend of $0.72 per share, providing a steady income stream for investors, with an annualized dividend yield of approximately 0.76%.

Cons of HCA Healthcare

  • The stock has recently experienced a decline of about 1.4%, which may signal volatility and potential challenges in the market.
  • Despite strong earnings, the company's price-to-earnings (PE) ratio is around 17.14, which could suggest that the stock is overvalued compared to its earnings.
  • Recent insider selling, including a significant transaction by the COO, may raise concerns about the company's future performance and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$90.66 billion
P/E Ratio
17.15
Consensus Rating
Moderate Buy
Consensus Price Target
$381.13 (+1.1% Upside)
Volume
1.14 million shares
Average Volume
1.44 million shares
Today's Range
$373.61
$377.46
50-Day Range
$317.93
$387.49
52-Week Range
$289.98
$417.14
Dividend Yield
0.74%
McKesson stock logo

23. McKesson NYSE:MCK

$715.44 +4.80 (+0.68%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$715.98 +0.54 (+0.08%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. recently reported earnings per share of $10.12, surpassing analyst expectations, indicating strong financial performance and effective management.
  • The company has shown significant revenue growth, with an 18.9% increase compared to the same quarter last year, suggesting a robust demand for its services.
  • The current stock price is around $720, reflecting a solid market position and investor confidence in the company's future prospects.

Cons of McKesson

  • Despite the revenue growth, McKesson Co. reported a negative return on equity of 181.26%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • The company has a relatively low net margin of 0.82%, indicating that a small percentage of revenue is converted into profit, which could limit growth potential.
  • Recent insider selling, including significant shares sold by the CEO, may signal a lack of confidence in the company's future performance from its leadership.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.91 billion
P/E Ratio
32.76
Consensus Rating
Moderate Buy
Consensus Price Target
$686.69 (-4.0% Downside)
Volume
815,972 shares
Average Volume
917,067 shares
Today's Range
$709.48
$718.25
50-Day Range
$652.88
$726.05
52-Week Range
$464.42
$731.00
Dividend Yield
0.40%
The Cigna Group stock logo

24. The Cigna Group NYSE:CI

$316.36 +3.68 (+1.18%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$310.75 -5.61 (-1.77%)
As of 05/23/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The current stock price is around $324.75, which may present a buying opportunity for investors looking for value in the health insurance sector.
  • Analysts have a consensus "Buy" rating for The Cigna Group, indicating strong confidence in the company's future performance.
  • Recent target price increases from analysts, such as Truist Financial raising their target to $405.00, suggest positive growth expectations for the company.

Cons of The Cigna Group

  • Insider sales have resulted in a significant decrease in ownership, with one insider selling 9,944 shares, which could raise concerns about the company's future performance.
  • Some analysts have lowered their target prices, such as Wells Fargo reducing theirs to $341.00, indicating potential caution regarding the stock's growth.
  • The company's current ratio of 0.66 suggests that it may have difficulty meeting short-term liabilities, which could be a red flag for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.51 billion
P/E Ratio
25.85
Consensus Rating
Buy
Consensus Price Target
$379.33 (+19.9% Upside)
Volume
1.67 million shares
Average Volume
1.71 million shares
Today's Range
$310.51
$316.59
50-Day Range
$301.90
$340.21
52-Week Range
$262.03
$370.83
Dividend Yield
1.86%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$372.33 -12.18 (-3.17%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$374.76 +2.43 (+0.65%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$84.12 billion
P/E Ratio
14.54
Consensus Rating
Moderate Buy
Consensus Price Target
$510.38 (+37.1% Upside)
Volume
2.48 million shares
Average Volume
1.53 million shares
Today's Range
$368.75
$386.29
50-Day Range
$372.33
$452.70
52-Week Range
$357.45
$567.26
Dividend Yield
1.66%
GSK stock logo

26. GSK NYSE:GSK

$38.70 -0.23 (-0.58%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$39.12 +0.42 (+1.10%)
As of 05/23/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $38.78, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc reported strong quarterly earnings, with revenue significantly exceeding analysts' expectations, indicating robust business performance.
  • The company has a solid market capitalization of approximately $80 billion, suggesting stability and a strong presence in the industry.

Cons of GSK

  • The stock has experienced fluctuations, with a 12-month high of $45.77 and a low of $31.72, indicating potential volatility that could concern risk-averse investors.
  • GSK plc's debt-to-equity ratio is 1.12, which suggests that the company has a relatively high level of debt compared to its equity, potentially increasing financial risk.
  • Despite recent revenue growth, the company's net margin of 8.13% may be lower than some competitors, raising questions about profitability efficiency.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.84 billion
P/E Ratio
24.34
Consensus Rating
Hold
Consensus Price Target
$40.58 (+4.9% Upside)
Volume
3.67 million shares
Average Volume
4.83 million shares
Today's Range
$38.61
$38.87
50-Day Range
$33.65
$39.83
52-Week Range
$31.72
$45.45
Dividend Yield
4.39%
CVS Health stock logo

27. CVS Health NYSE:CVS

$60.80 +0.58 (+0.96%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$60.76 -0.04 (-0.07%)
As of 05/23/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The company recently reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial health and operational efficiency.
  • CVS Health Co. has shown a solid revenue growth of approximately 7% compared to the same quarter last year, suggesting a positive trend in business performance.
  • The current stock price is around $74, which is near the average price target set by analysts, indicating potential for further appreciation.

Cons of CVS Health

  • The company has a relatively low net margin of 1.24%, which may indicate challenges in maintaining profitability amidst rising operational costs.
  • CVS Health Co. has a debt-to-equity ratio of 0.80, suggesting that the company is somewhat reliant on debt financing, which could pose risks if interest rates rise.
  • Despite recent growth, the stock has experienced volatility, which may deter risk-averse investors looking for stable investments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.91 billion
P/E Ratio
16.61
Consensus Rating
Moderate Buy
Consensus Price Target
$75.27 (+23.8% Upside)
Volume
8.14 million shares
Average Volume
11.33 million shares
Today's Range
$59.66
$60.88
50-Day Range
$60.03
$70.40
52-Week Range
$43.56
$72.51
Dividend Yield
4.25%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$162.92 +0.95 (+0.59%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$162.29 -0.63 (-0.39%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $162.45, which reflects a stable market position and potential for growth.
  • Zoetis Inc. has recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and effective management.
  • The company has a solid market capitalization of approximately $72.32 billion, suggesting it is a well-established player in the animal health industry.

Cons of Zoetis

  • Despite recent positive earnings, the stock has shown fluctuations, which may indicate volatility and risk for potential investors.
  • Insider selling activity, including significant sales by directors, could raise concerns about the company's future outlook and insider confidence.
  • The company's price-to-earnings ratio of 29.69 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.53 billion
P/E Ratio
29.78
Consensus Rating
Buy
Consensus Price Target
$212.75 (+30.6% Upside)
Volume
2.73 million shares
Average Volume
2.53 million shares
Today's Range
$160.14
$163.06
50-Day Range
$144.09
$165.12
52-Week Range
$139.70
$200.33
Dividend Yield
1.25%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$588.34 -8.51 (-1.43%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$591.22 +2.88 (+0.49%)
As of 05/23/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. has a strong net margin of over 30%, indicating efficient management and profitability, which can lead to higher returns for investors.
  • The company has a solid return on equity of 16.32%, suggesting that it effectively uses shareholders' equity to generate profits.

Cons of Regeneron Pharmaceuticals

  • The company reported a decline in revenue of about 3.7% compared to the same quarter last year, which may indicate challenges in maintaining sales growth.
  • Recent earnings per share fell short of analysts' expectations, which could signal potential issues in meeting future financial targets.
  • Analysts have adjusted their price targets downward, reflecting a more cautious outlook on the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.52 billion
P/E Ratio
15.37
Consensus Rating
Moderate Buy
Consensus Price Target
$890.60 (+51.4% Upside)
Volume
655,734 shares
Average Volume
799,208 shares
Today's Range
$582.37
$591.64
50-Day Range
$527.78
$672.36
52-Week Range
$520.50
$1,211.20
Dividend Yield
0.15%
Cencora stock logo

30. Cencora NYSE:COR

$292.23 +2.12 (+0.73%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$293.18 +0.95 (+0.33%)
As of 05/23/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is approximately $289, which reflects a strong market position and potential for growth.
  • Insider ownership stands at 10.80%, indicating that executives have a significant stake in the company, aligning their interests with those of shareholders.
  • Recent insider transactions show that executives are actively managing their holdings, which can signal confidence in the company's future performance.

Cons of Cencora

  • Recent insider sales, while indicating confidence, also represent a decrease in ownership, which could raise concerns about future performance.
  • There has been a notable decrease in positions held by executives, with some selling over 24% of their shares, which may suggest a lack of confidence in the stock's short-term prospects.
  • The pharmaceutical distribution sector can be highly competitive, and any shifts in regulations or market dynamics could impact profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.64 billion
P/E Ratio
41.57
Consensus Rating
Moderate Buy
Consensus Price Target
$301.18 (+3.1% Upside)
Volume
1.36 million shares
Average Volume
1.54 million shares
Today's Range
$289.23
$293.42
50-Day Range
$266.10
$304.04
52-Week Range
$214.77
$309.35
Dividend Yield
0.76%
Haleon stock logo

31. Haleon NYSE:HLN

$11.16 +0.10 (+0.90%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$11.14 -0.02 (-0.13%)
As of 05/23/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The company recently reported earnings per share (EPS) of $0.05, exceeding analyst expectations, which indicates strong financial performance.
  • Haleon plc has a solid revenue of $3.54 billion for the quarter, surpassing estimates, showcasing its ability to generate significant sales.
  • The current stock price is around $10.68, reflecting a positive market sentiment and potential for growth.

Cons of Haleon

  • Despite recent growth, the stock has a price-to-earnings (P/E) ratio of 31.40, which may indicate that it is overvalued compared to its earnings.
  • The company has a debt-to-equity ratio of 0.44, which, while manageable, suggests some reliance on debt financing that could pose risks in a rising interest rate environment.
  • Institutional investors and hedge funds own only 6.67% of the company's stock, indicating a lack of confidence from larger investment entities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.31 billion
P/E Ratio
32.82
Consensus Rating
Moderate Buy
Consensus Price Target
$11.25 (+0.8% Upside)
Volume
20.77 million shares
Average Volume
8.23 million shares
Today's Range
$11.05
$11.19
50-Day Range
$9.28
$11.16
52-Week Range
$8.25
$11.19
Dividend Yield
2.19%
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$171.49 -0.82 (-0.47%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$171.06 -0.43 (-0.25%)
As of 05/23/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $176.72, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Becton, Dickinson and Company has a strong market capitalization of approximately $50.65 billion, indicating a solid position in the industry and potential for growth.
  • Recent analyst ratings show a mix of buy and hold recommendations, suggesting that there is still confidence in the company's future performance despite recent downgrades.

Cons of Becton, Dickinson and Company

  • Recent downgrades from multiple analysts, including a shift from "buy" to "neutral" ratings, may indicate a lack of confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a fifty-two week low of $163.33, suggesting potential volatility that could deter risk-averse investors.
  • Insider selling activity, with executives recently selling shares, could signal concerns about the company's future prospects or performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.15 billion
P/E Ratio
28.49
Consensus Rating
Hold
Consensus Price Target
$221.44 (+29.1% Upside)
Volume
1.95 million shares
Average Volume
1.93 million shares
Today's Range
$169.60
$172.16
50-Day Range
$165.13
$231.94
52-Week Range
$163.33
$251.99
Dividend Yield
2.37%
Takeda Pharmaceutical stock logo

33. Takeda Pharmaceutical NYSE:TAK

$14.58 +0.17 (+1.15%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$14.56 -0.01 (-0.07%)
As of 05/23/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Recent upgrades from analysts, such as Morgan Stanley raising its rating from "equal weight" to "overweight," suggest positive sentiment and potential for stock appreciation.
  • The current stock price is around $13.86, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has a solid market capitalization of approximately $44.10 billion, indicating a stable presence in the market.

Cons of Takeda Pharmaceutical

  • The company missed earnings per share estimates by $0.08, reporting only $0.16, which may raise concerns about its financial performance.
  • Revenue for the latest quarter was $7.34 billion, falling short of the consensus estimate of $8.02 billion, indicating potential challenges in meeting growth expectations.
  • Takeda's quick ratio of 0.72 suggests potential liquidity issues, as it indicates the company may not have enough short-term assets to cover its short-term liabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.38 billion
P/E Ratio
36.44
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.99 million shares
Average Volume
1.93 million shares
Today's Range
$14.45
$14.59
50-Day Range
$13.69
$15.38
52-Week Range
$12.58
$15.43
Dividend Yield
3.82%
Edwards Lifesciences stock logo

34. Edwards Lifesciences NYSE:EW

$74.98 +0.19 (+0.25%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$75.09 +0.11 (+0.15%)
As of 05/23/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $74.80, which may present a buying opportunity for investors looking for growth in the medical research sector.
  • Recent institutional investments, including a significant increase by Vident Advisory LLC, indicate strong confidence in the company's future performance.
  • Edwards Lifesciences Co. reported a revenue increase of 6.2% compared to the same quarter last year, showcasing its ability to grow even in competitive markets.

Cons of Edwards Lifesciences

  • Insider selling has been notable, with executives selling over 66,000 shares recently, which may raise concerns about their confidence in the company's future.
  • The stock has experienced volatility, with a one-year high of $95.25 and a low of $58.93, indicating potential risks for investors looking for stability.
  • Despite recent revenue growth, the company's price-to-earnings ratio of 10.92 may suggest that the stock is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.98 billion
P/E Ratio
10.76
Consensus Rating
Hold
Consensus Price Target
$80.20 (+7.0% Upside)
Volume
3.74 million shares
Average Volume
5.14 million shares
Today's Range
$74.20
$75.15
50-Day Range
$67.04
$78.02
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
Alcon stock logo

35. Alcon NYSE:ALC

$86.54 +0.40 (+0.47%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$86.52 -0.02 (-0.02%)
As of 05/23/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is approximately $91.50, reflecting a strong market position and potential for growth.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a solid upward trend in its stock value.
  • Institutional ownership is significant, suggesting that large investors have confidence in the company's future prospects.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which may indicate reduced trading interest.
  • The company has experienced fluctuations in shares shorted, which could suggest uncertainty among some investors.
  • While institutional ownership is high, it also means that a significant portion of shares is held by a few entities, which can lead to volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.69 billion
P/E Ratio
36.98
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+22.6% Upside)
Volume
1.20 million shares
Average Volume
1.11 million shares
Today's Range
$85.00
$86.61
50-Day Range
$82.86
$98.39
52-Week Range
$80.48
$101.10
Dividend Yield
0.28%
IDEXX Laboratories stock logo

36. IDEXX Laboratories NASDAQ:IDXX

$501.57 -3.26 (-0.65%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$501.54 -0.03 (-0.01%)
As of 05/23/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $500, reflecting strong market interest and potential for growth.
  • IDEXX Laboratories, Inc. reported a quarterly earnings per share (EPS) of $2.96, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a high return on equity of 55.82%, suggesting effective management and profitability relative to shareholder equity.

Cons of IDEXX Laboratories

  • The stock has a relatively high price-to-earnings (PE) ratio of around 47, which may indicate that it is overvalued compared to its earnings.
  • Fluctuations in stock price have been observed, with recent trading showing a decline of about $16, which could signal volatility.
  • Institutional investors hold a significant 87.84% of the stock, which may limit individual investors' influence on stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.34 billion
P/E Ratio
47.01
Consensus Rating
Moderate Buy
Consensus Price Target
$536.00 (+6.9% Upside)
Volume
443,606 shares
Average Volume
649,917 shares
Today's Range
$496.61
$502.18
50-Day Range
$361.04
$521.68
52-Week Range
$356.14
$530.60
Dividend Yield
N/A
Veeva Systems stock logo

37. Veeva Systems NYSE:VEEV

$233.41 -2.12 (-0.90%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$230.56 -2.85 (-1.22%)
As of 05/23/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $235, reflecting a stable market position and potential for growth.
  • Veeva Systems Inc. has received multiple upgrades from analysts, indicating strong confidence in its future performance.
  • The company has a solid market capitalization of approximately $38.31 billion, suggesting it is a well-established player in the life sciences software sector.

Cons of Veeva Systems

  • Some analysts have downgraded the stock from "buy" to "sell," which may indicate concerns about future performance.
  • Insider sales have occurred recently, with significant shares sold, which could suggest a lack of confidence among executives.
  • The stock has experienced fluctuations, with a twelve-month high of $258.93 and a low of $170.25, indicating volatility that may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.97 billion
P/E Ratio
57.63
Consensus Rating
Moderate Buy
Consensus Price Target
$254.92 (+9.2% Upside)
Volume
858,455 shares
Average Volume
1.11 million shares
Today's Range
$232.15
$234.53
50-Day Range
$209.34
$242.48
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

38. Alnylam Pharmaceuticals NASDAQ:ALNY

$289.96 +0.96 (+0.33%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$291.15 +1.19 (+0.41%)
As of 05/23/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Recent analyst upgrades have increased target prices significantly, with some analysts setting targets as high as $353.00, indicating strong market confidence in the company's future performance.
  • The current stock price is around $291.68, which is near its 52-week high of $304.39, suggesting potential for further growth as the company continues to develop its innovative therapeutics.
  • Alnylam Pharmaceuticals, Inc. reported a revenue increase of over 20% year-over-year, demonstrating strong business growth and demand for its products.

Cons of Alnylam Pharmaceuticals

  • The company reported a loss of $0.44 earnings per share, which was below the consensus estimate, indicating challenges in achieving profitability in the near term.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio of 15.27, which may raise concerns about financial leverage and the risks associated with high levels of debt.
  • Despite revenue growth, the company has not yet achieved positive earnings, which could deter risk-averse investors looking for stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.81 billion
P/E Ratio
-133.62
Consensus Rating
Moderate Buy
Consensus Price Target
$319.17 (+10.1% Upside)
Volume
757,018 shares
Average Volume
917,014 shares
Today's Range
$284.19
$291.22
50-Day Range
$224.32
$292.58
52-Week Range
$146.79
$304.39
Dividend Yield
N/A
Cardinal Health stock logo

39. Cardinal Health NYSE:CAH

$152.72 +0.24 (+0.15%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$153.18 +0.46 (+0.30%)
As of 05/23/2025 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $153, reflecting a strong performance in the market.
  • Recent earnings results showed a significant earnings per share (EPS) of $2.35, surpassing analysts' expectations, indicating robust financial health.
  • Cardinal Health, Inc. has received multiple upgrades from analysts, with price targets raised to as high as $170, suggesting strong future growth potential.

Cons of Cardinal Health

  • The company has a negative return on equity of 59.57%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Despite recent revenue growth, the company reported revenues that fell short of analysts' expectations, which could indicate challenges in meeting market demands.
  • Cardinal Health, Inc. has a relatively low net margin of 0.59%, suggesting that it may not be as profitable as some of its competitors in the healthcare industry.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.45 billion
P/E Ratio
28.49
Consensus Rating
Moderate Buy
Consensus Price Target
$146.43 (-4.1% Downside)
Volume
1.86 million shares
Average Volume
2.23 million shares
Today's Range
$150.77
$153.15
50-Day Range
$124.87
$154.71
52-Week Range
$93.17
$156.44
Dividend Yield
1.31%
argenx stock logo

40. argenx NASDAQ:ARGX

$587.61 +6.17 (+1.06%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$633.50 +45.89 (+7.81%)
As of 05/23/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • The current stock price is around $563, which may present a buying opportunity for investors looking for growth in the biotech sector.
  • Recent upgrades from analysts, including a shift to an "outperform" rating, indicate positive sentiment and potential for stock appreciation.
  • Institutional ownership stands at over 60%, suggesting confidence from major investors in the company's future performance.

Cons of argenx

  • Despite positive analyst ratings, the stock has experienced volatility, with a twelve-month high of $678.21 and a low of $356.38, indicating potential risk.
  • Some analysts have lowered their price targets, which may signal caution regarding the company's near-term performance.
  • The biotech sector can be highly unpredictable, with regulatory challenges and market competition posing risks to argenx SE's growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.88 billion
P/E Ratio
-667.74
Consensus Rating
Buy
Consensus Price Target
$698.11 (+18.8% Upside)
Volume
227,615 shares
Average Volume
324,850 shares
Today's Range
$576.31
$588.37
50-Day Range
$532.27
$656.65
52-Week Range
$358.80
$678.21
Dividend Yield
N/A
ResMed stock logo

41. ResMed NYSE:RMD

$243.03 -2.46 (-1.00%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$241.60 -1.43 (-0.59%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. recently reported strong quarterly earnings, with earnings per share (EPS) of $2.37, slightly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue growth of approximately 7.9%, reflecting its ability to expand and capture market share in the medical equipment sector.
  • ResMed Inc. has a solid return on equity of 26.17%, which suggests effective management and a strong ability to generate profits from shareholders' equity.

Cons of ResMed

  • Insider selling has been notable, with insiders selling nearly 49,000 shares recently, which may raise concerns about the company's future prospects from those closest to it.
  • The stock has experienced a decline of about 1.5% recently, which could indicate short-term volatility and investor uncertainty.
  • Despite strong earnings, the company's price-to-earnings (P/E) ratio of 29.48 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.63 billion
P/E Ratio
28.69
Consensus Rating
Moderate Buy
Consensus Price Target
$259.33 (+6.7% Upside)
Volume
558,144 shares
Average Volume
1.02 million shares
Today's Range
$242.22
$245.50
50-Day Range
$204.54
$252.96
52-Week Range
$179.42
$263.05
Dividend Yield
0.84%
DexCom stock logo

42. DexCom NASDAQ:DXCM

$84.51 -0.32 (-0.38%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$83.78 -0.73 (-0.86%)
As of 05/23/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $85.48, which reflects a strong market interest in the company's continuous glucose monitoring systems.
  • Recent analyst ratings indicate a consensus of "Moderate Buy," with a significant number of analysts issuing buy ratings, suggesting positive market sentiment.
  • DexCom, Inc. reported a revenue increase of 12.5% compared to the same quarter last year, indicating strong growth potential in the medical device sector.

Cons of DexCom

  • The company recently missed earnings expectations by a small margin, which could raise concerns about its short-term financial performance.
  • Insider selling activity has been noted, with significant shares sold by executives, which may signal a lack of confidence in the stock's near-term performance.
  • The stock has a high P/E ratio of 59.78, indicating that it may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.14 billion
P/E Ratio
59.10
Consensus Rating
Moderate Buy
Consensus Price Target
$98.00 (+16.0% Upside)
Volume
2.60 million shares
Average Volume
4.36 million shares
Today's Range
$83.48
$85.01
50-Day Range
$59.83
$87.34
52-Week Range
$57.52
$128.63
Dividend Yield
N/A
GE HealthCare Technologies stock logo

43. GE HealthCare Technologies NASDAQ:GEHC

$69.16 -0.28 (-0.40%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$69.26 +0.10 (+0.14%)
As of 05/23/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported earnings per share of $1.01, exceeding analysts' expectations, indicating strong financial performance.
  • GE HealthCare Technologies Inc. has a robust return on equity of 25.74%, suggesting effective management and profitability relative to shareholder equity.
  • The current stock price is around $70.87, which is below its 200-day moving average of $79.96, potentially indicating a buying opportunity for investors.

Cons of GE HealthCare Technologies

  • Analysts have recently adjusted their price targets downward, with some estimates dropping significantly, which may indicate a lack of confidence in future growth.
  • The dividend yield is relatively low at 0.20%, which may not attract income-focused investors looking for higher returns from dividends.
  • Despite positive earnings, the company’s net margin of 10.13% may suggest limited profitability compared to industry peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.67 billion
P/E Ratio
15.97
Consensus Rating
Moderate Buy
Consensus Price Target
$88.27 (+27.6% Upside)
Volume
2.49 million shares
Average Volume
3.44 million shares
Today's Range
$68.44
$69.36
50-Day Range
$58.75
$82.46
52-Week Range
$57.65
$94.80
Dividend Yield
0.19%
Agilent Technologies stock logo

44. Agilent Technologies NYSE:A

$108.61 -1.07 (-0.97%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$108.52 -0.10 (-0.09%)
As of 05/23/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $113.76, which may present a buying opportunity for investors looking for value.
  • Agilent Technologies, Inc. has received a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock.
  • The company has a solid dividend yield of 0.87%, which can provide a steady income stream for investors.

Cons of Agilent Technologies

  • Recent target price reductions by analysts, including a drop to $115.00, may indicate concerns about the company's near-term performance.
  • Insider selling activity, such as the recent sale of shares by a director, could signal a lack of confidence in the stock's future performance.
  • The stock has experienced volatility, with a 52-week high of $154.95 and a low of $96.43, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.97 billion
P/E Ratio
24.97
Consensus Rating
Hold
Consensus Price Target
$141.42 (+30.2% Upside)
Volume
1.69 million shares
Average Volume
1.92 million shares
Today's Range
$107.07
$109.06
50-Day Range
$98.97
$122.27
52-Week Range
$96.43
$153.84
Dividend Yield
0.91%
Centene stock logo

45. Centene NYSE:CNC

$56.42 -1.65 (-2.83%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$56.74 +0.32 (+0.56%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is around $61.78, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Centene Co. reported strong quarterly earnings, with earnings per share (EPS) of $2.90, exceeding expectations and indicating robust financial health.
  • The company has shown significant revenue growth, with a 15.4% increase compared to the same quarter last year, suggesting strong demand for its services.

Cons of Centene

  • Several analysts have downgraded their ratings on Centene Co., indicating a shift in market sentiment that could affect stock performance.
  • The company's debt-to-equity ratio is 0.70, which, while manageable, suggests a reliance on debt that could pose risks in a rising interest rate environment.
  • Despite recent revenue growth, the net margin of 2.03% indicates that profit margins are relatively thin, which could limit the company's ability to weather economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.08 billion
P/E Ratio
9.04
Consensus Rating
Moderate Buy
Consensus Price Target
$79.77 (+41.4% Upside)
Volume
5.21 million shares
Average Volume
4.89 million shares
Today's Range
$55.79
$58.52
50-Day Range
$56.43
$64.37
52-Week Range
$55.03
$80.59
Dividend Yield
N/A
Humana stock logo

46. Humana NYSE:HUM

$224.81 -2.33 (-1.02%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$225.00 +0.19 (+0.08%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $255, showing a recent increase, which may indicate positive market sentiment towards the company.
  • Humana Inc. has seen significant institutional investment, with over 92% of its stock owned by institutional investors and hedge funds, suggesting strong confidence in the company's future performance.
  • Recent analyst upgrades, including a "buy" rating from Guggenheim and an upgrade from StockNews.com, reflect positive expectations for the company's growth and profitability.

Cons of Humana

  • Despite recent positive movements, the stock has a twelve-month high of $406.46, indicating it has experienced significant volatility, which may concern risk-averse investors.
  • Analysts have issued mixed ratings, with a consensus rating of "Hold," suggesting that while there is potential, there may also be caution regarding the stock's future performance.
  • The company has a debt-to-equity ratio of 0.68, which, while manageable, indicates that it does carry some debt, potentially impacting its financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.13 billion
P/E Ratio
22.59
Consensus Rating
Hold
Consensus Price Target
$286.81 (+27.6% Upside)
Volume
1.67 million shares
Average Volume
1.78 million shares
Today's Range
$222.22
$229.01
50-Day Range
$224.81
$294.97
52-Week Range
$212.45
$406.46
Dividend Yield
1.39%
Beigene stock logo

47. Beigene NASDAQ:ONC

$241.43 +2.67 (+1.12%)
As of 05/23/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Market Capitalization
$23.91 billion
P/E Ratio
-29.30
Consensus Rating
Buy
Consensus Price Target
$319.00 (+32.1% Upside)
Volume
171,472 shares
Average Volume
466,365 shares
Today's Range
$237.13
$242.94
50-Day Range
$206.32
$274.78
52-Week Range
$141.31
$287.88
Dividend Yield
N/A
STERIS stock logo

48. STERIS NYSE:STE

$243.21 -0.59 (-0.24%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$242.96 -0.24 (-0.10%)
As of 05/23/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. More about STERIS

Pros of STERIS

  • STERIS plc recently reported earnings per share of $2.74, exceeding expectations, which indicates strong financial performance and effective management.
  • The company has shown a year-over-year revenue growth of approximately 5.7%, suggesting a positive trend in its business operations and market demand.
  • With a current stock price around $246, STERIS plc is positioned within a reasonable range for potential growth, especially given its market capitalization of $24.20 billion.

Cons of STERIS

  • The stock has experienced fluctuations, with a recent trading drop of about $4.18, which may indicate volatility and potential risks for investors.
  • Despite positive earnings, the company's P/E ratio stands at 52.29, which is relatively high and may suggest that the stock is overvalued compared to its earnings.
  • STERIS plc operates in a competitive medical equipment market, which could impact its market share and profitability if competitors introduce superior products.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$23.90 billion
P/E Ratio
51.64
Consensus Rating
Moderate Buy
Consensus Price Target
$264.00 (+8.5% Upside)
Volume
538,496 shares
Average Volume
543,515 shares
Today's Range
$242.10
$244.02
50-Day Range
$208.26
$252.31
52-Week Range
$200.98
$252.79
Dividend Yield
0.91%
BioNTech stock logo

49. BioNTech NASDAQ:BNTX

$98.68 -0.39 (-0.39%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$98.36 -0.33 (-0.33%)
As of 05/23/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • BioNTech SE recently reported earnings per share significantly above consensus estimates, indicating strong financial performance and potential for growth.
  • The stock price is currently around $98, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Analysts have a consensus rating of "Moderate Buy" for BioNTech SE, with several firms setting target prices above the current stock price, suggesting potential upside.

Cons of BioNTech

  • The company has reported a negative net margin, indicating that it is currently spending more than it earns, which could be a concern for profitability.
  • Revenue has decreased compared to the same quarter last year, suggesting potential challenges in maintaining sales momentum.
  • Analysts predict a negative earnings per share for the current year, which may indicate ongoing financial difficulties.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$23.72 billion
P/E Ratio
-46.99
Consensus Rating
Moderate Buy
Consensus Price Target
$141.73 (+43.6% Upside)
Volume
598,407 shares
Average Volume
921,427 shares
Today's Range
$96.38
$98.88
50-Day Range
$86.65
$120.54
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
IQVIA stock logo

50. IQVIA NYSE:IQV

$136.96 -1.08 (-0.78%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$137.13 +0.16 (+0.12%)
As of 05/23/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $137, which is significantly lower than its 12-month high of $252.88, potentially offering a buying opportunity for investors looking for value.
  • IQVIA Holdings Inc. reported a strong quarterly earnings result, with an EPS of $2.70, exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue growth of 2.5%, reflecting its ability to expand and adapt in the competitive medical research sector.

Cons of IQVIA

  • The stock has experienced a decline of about 5.3% recently, which may indicate volatility and potential risks for investors.
  • With a debt-to-equity ratio of 2.12, the company has a relatively high level of debt compared to its equity, which could pose financial risks in adverse market conditions.
  • The current ratio and quick ratio are both at 0.84, suggesting that the company may face challenges in meeting its short-term liabilities, which could be a concern for liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$23.69 billion
P/E Ratio
18.26
Consensus Rating
Moderate Buy
Consensus Price Target
$228.14 (+66.6% Upside)
Volume
2.25 million shares
Average Volume
1.56 million shares
Today's Range
$134.65
$137.88
50-Day Range
$136.96
$186.80
52-Week Range
$134.65
$252.88
Dividend Yield
N/A